Please ensure Javascript is enabled for purposes of website accessibility

Pfizer and BioNTech Begin U.S. Trials of SARS-CoV-2 Vaccine Candidate

By Cory Renauer – May 5, 2020 at 1:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clinical trials of their experimental vaccine to prevent COVID-19 started in Germany last month.

BioNTech (BNTX 2.34%) and Pfizer (PFE 0.54%) have dosed the first two U.S. volunteers with a vaccine candidate that could protect people from the coronavirus responsible for COVID-19. The partners began the global clinical trial of the vaccine in April, when they dosed a group of patients in Germany.

Trying something different 

Traditional drug development is a long process featuring clearly defined steps -- and BioNTech and Pfizer aren't exactly following them. For example, instead of carefully winnowing down its potential treatments to a single COVID-19 vaccine candidate to advance into human studies, the partners will dose people with four related vaccine candidates during the early stages of clinical trials.

Healthcare professional in personal protective equipment.

Image source: Getty Images.

The BNT162 vaccine program is enrolling patients aged 18 to 55 and  65 to 85 in separate groups that will be injected with the new vaccine candidates at increasing doses. Patients in the younger cohorts will try ascending dosages before they're given to the older patient groups.

Thinking ahead

During BNT162's clinical development, BioNTech will supply investigators with vaccine candidates produced in its European facilities. To prepare for widespread distribution in the event the program succeeds,  the partners are prepared to invest in developing large-scale manufacturing capacity before any trial results are in.

Pfizer-owned sites in three U.S. states and another in Belgium have been identified as potential SARS-CoV-2 vaccine production centers. BioNTech has a couple of sites in Germany that could add to partners' manufacturing capacity.

With multiple sites scaling up production of BNT162 before anybody knows if it works, the partners will be ready to manufacture millions of doses before the end of 2020, and hundreds of millions in 2021.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.33 (0.54%) $0.24
BioNTech SE Stock Quote
BioNTech SE
BNTX
$133.35 (2.34%) $3.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.